Corvus Pharmaceuticals Inc CRVS
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-03-23 |
| Shares Out. | 84,090,000 |
| Website | corvuspharma.com/ ↗ |
| Phone | 13026587581 |
| Employees | 37 |
| Net Income | -$13.7M |
| Free Cash Flow | -$35.1M |
| Total Assets | $253.2M |
| Total Liabilities | $12.5M |
| Equity | $240.7M |
About Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing product candidates that precisely target proteins that are critical to immune cell maturation and function. It believes its proprietary product candidates have broad potential to address immune mediated diseases, inflammatory diseases and cancers. Its product candidate, soquelitinib, is designed to bind specifically to a protein, interleukin 2 inducible T cell kinase (ITK), involved in T cell activation, T cell receptor signaling and T cell differentiation and function. The company operates in one primary business activity and operate as one reportable segment.
Corvus Pharmaceuticals Inc is a publicly traded company under the ticker symbol CRVS on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
13 analysts (2026-07-01)